Edit
Stevenage Bioscience Catalyst
https://www.stevenagecatalyst.comLast activity: 22.05.2026
Active
Stevenage Bioscience Catalyst is a leading location for companies to develop and commercialise cutting edge therapeutics.
The Campus is home to major organisations including GSK, the Cell & Gene Therapy Manufacturing Catapult, LifeArc and GE alongside a growing cluster of academics and start-up companies which together have raised over £1bn in funding.
The facilities have been designed to foster cooperation, scientific and commercial dialogue and interaction between entrepreneurs. Access is offered to business support, equipment and facilities that would otherwise be beyond the reach of small or medium-sized companies.
The Campus is home to major organisations including GSK, the Cell & Gene Therapy Manufacturing Catapult, LifeArc and GE alongside a growing cluster of academics and start-up companies which together have raised over £1bn in funding.
The facilities have been designed to foster cooperation, scientific and commercial dialogue and interaction between entrepreneurs. Access is offered to business support, equipment and facilities that would otherwise be beyond the reach of small or medium-sized companies.
Location: United Kingdom, England, Stevenage
Employees: 1-10
Founded date: 2012
Investment Type: Accelerator
Mentions in press and media 13
| Date | Title | Description |
| 22.05.2026 | Cambridge Wide Open Week 2026 announces top-tier keynotes & participating ventures for new expanded format | Cambridge Wide Open Week 2026 has unveiled further details of its highly anticipated June 11–19 event as the life sciences festival expands across the UK’s innovation “Golden Triangle” for the very first time. Keynote speakers for the event... |
| 02.03.2022 | Stevenage Bioscience Catalyst launches accelerator programme for biotech start-ups with opportunity for £10,000 award | Stevenage Bioscience Catalyst (SBC) launches an accelerator programme to give start-ups working on data-enabled drug discovery, genomics and advanced therapies the skills they need to get potential new drugs and therapies to market more qui... |
| 09.12.2021 | Report demonstrates Stevenage Bioscience Catalyst’s key role in delivering the economic benefit from leading edge UK life sciences | Report demonstrates Stevenage Bioscience Catalyst’s key role in delivering the economic benefit from leading edge UK life sciences 09-12-2021 An independent report has been released today by Stevenage Bioscience Catalyst (SBC) that demonstr... |
| 18.11.2021 | Biotech start-ups successfully graduate from DATA accelerator programme at Stevenage Bioscience Catalyst | Biotech start-ups successfully graduate from DATA accelerator programme at Stevenage Bioscience Catalyst 18-11-2021 Fifteen start-ups with huge potential have successfully completed the Data-driven Advanced Therapeutics Accelerator (DATA) p... |
| 23.02.2021 | Stevenage Bioscience Catalyst launches accelerator programme for biotech start-ups | Stevenage Bioscience Catalyst launches accelerator programme for biotech start-ups 23-02-2021 Stevenage Bioscience Catalyst (SBC) has launched a free accelerator programme to give data-focused biotech start-ups the skills they need to get p... |
| 03.01.2021 | Dr Sally Ann Forsyth CEO Stevenage Bioscience Catalyst awarded OBE | Dr Sally Ann Forsyth CEO Stevenage Bioscience Catalyst awarded OBE 03-01-2021 Dr Sally Ann Forsyth, CEO of Stevenage Bioscience Catalyst (SBC), thanks her colleagues and collaborators after being honoured in the 2021 New Year Honours list. ... |
| 24.11.2020 | Stevenage Bioscience Catalyst opens the Lab Hotel | Stevenage Bioscience Catalyst opens the Lab Hotel 24-11-2020 Stevenage Bioscience Catalyst (SBC), a leading location for development and commercialisation of cutting-edge therapeutics, is pleased to announce the opening of the Lab Hotel, a ... |
| 01.09.2020 | SBC company ReViral raises $44 million in Series C financing | SBC company ReViral raises $44 million in Series C financing 01-09-2020 London & Research Triangle Park, N.C. - ReViral Ltd., a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiv... |
| 05.01.2017 | NeRRe Therapeutics Raises £23M in Series B Financing | NeRRe Therapeutics, a Stevenage, England, UK-based clinical-stage company, raised £23m in Series B financing. The round was led by new investor Fountain Healthcare Partners, and co-led by Forbion Capital Partners and OrbiMed. Existing inves... |
| 16.10.2013 | MRC Technology to join innovation network at Stevenage Bioscience Catalyst | MRC Technology to join innovation network at Stevenage Bioscience Catalyst 16-10-2013 Stevenage Bioscience Catalyst (SBC), the UK’s first open innovation bioscience campus, and MRC Technology, a life science technology transfer organisation... |
Show more